Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus

Open access
Striepe, Kristina, Jumar, Agnes, Ott, Christian, Karg, Marina V., Schneider, Markus P., Kannenkeril, Dennis, Schmieder, Roland E. · 2017 · Circulation

Abstract

rom a clinical perspective, type 2 diabetes mellitus might also be regarded as a vascular disease, characterized by increased arterial stiffness.Empagliflozin is a selective sodium-glucose cotransporter 2 inhibitor shown to improve glycemic control after short-and long-term treatment.1 In the EMPA-REG OUTCOME study (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), a prospective randomized double-blind study in patients with type 2 diabetes mellitus with established cardiovascular disease, treatment with empagliflozin reduced the primary combined cardiovascular end point (3P-MACE [3-point major adverse cardiovascular event]), as well as secondary end points of hospitalization because of heart failure, cardiovascular morbidity, total mortality, and renal end points.2 We tested the hypothesis that improvements of vascular function and stiffness are involved in the observed improved cardiovascular and renal outcomes with empagliflozin treatment.In this investigator-initiated prospective, double-blind, randomized, placebocontrolled, crossover, interventional single-center trial, 76 female and male patients (18-75 years of age) with diagnosed type 2 diabetes mellitus were randomized to either empagliflozin 25 mg orally once daily or placebo for 6 weeks, followed by the second 6-week treatment with the other compound (crossover).In 64 patients, any antidiabetic agent was withdrawn 4 weeks before the baseline examination.We analyzed the effects of empagliflozin on central hemodynamics and vascular function at baseline (untreated status), after 6 weeks with empafliflozin/placebo, and after another 6 weeks with the other compound.The study protocol was approved by the local ethics committee, and written informed consent was obtained.To measure central systolic pressure and central pulse pressure, radial artery waveforms were recorded by the SphygmoCor System (AtCor Medical), and corresponding central (aortic) waveforms were then automatically generated through a validated transfer function.3 During 24-hour ambulatory, daily-life conditions, brachial blood pressure (BP), and derived central (aortic) pressure curves (obtained through a validated transfer function) were assessed by the Mobilograph (IEM).4 Statistical analysis was performed in the per protocol population (N=71).All patients (59% males, 62±7 years of age) were white, and 10 patients had established cardiovascular disease.At baseline, HbA1c was 6.75±0.8%,body weight 89.2 kg, office BP 129±14/77±7.6mm Hg, and ambulatory BP 129±10/79±7.1 mm Hg.Compared with placebo, empagliflozin effected a decrease of HbA1c (-0.26±0.44%,P=0.001), fasting glucose (-24.9±26mg/dL, P<0.001), body weight (-1.08±1.5 kg, P<0.001), brachial office BP (-5.20±7.8/-1.70±6.1 mm Hg, P<0.001/P=0.021),and 24-hour ambulatory BP (-2.13±7.3/-1.93±5.1 mm Hg, P=0.017/0.002).No safety issues were noted throughout the study.Under office conditions, central systolic (primary objective) and central pulse were lower by 5.14 mm Hg (P<0.001) in the empagliflozin group than in the placebo group after 6 weeks of treatment (Figure).Accordingly, a decreased forward pressure wave amplitude and a reduced reflected pressure wave amplitude were

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.029529

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 169

Metadata

Authors
Striepe, K., Jumar, A., Ott, C., Karg, M. V., Schneider, M. P., Kannenkeril, D., & Schmieder, R. E.
Venue
Circulation
Published
2017-09-19
Volume
136
Issue
12
Pages
1167-1169
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2755863750
Cited by
169
References
2
FWCI
8.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.